Compare Moderna, Inc. (MRNA) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs IAC/Interactivecorp — how do they compare? Moderna, Inc. trades at $61.35 (market cap $24.18B), while IAC/Interactivecorp trades at $40.17 (market cap $2.97B). The key difference: Moderna, Inc. is far larger — about 8.1× IAC/Interactivecorp's market cap, and Moderna, Inc. is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| MRNA | PPLI | |
|---|---|---|
Market Cap | $24.18B | $2.97B |
Sector | Health | Media |
52-Week High | $81.80 | $47.62 |
52-Week Low | $22.36 | $31.52 |
Enterprise Value | $20.33B | $3.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
PPLI trades at $40.66, down 2.21% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by digital growth and MGM investment gains. The company is simplifying its structure and monetizing non-core assets. Valuation ratios appear attractive with a P/E of 6.76 and P/B of 0.59, though revenue has declined from $5.2B in 2022 to $2.4B in 2025.
Outlook is mixed: low valuation and asset monetization offer upside, but declining revenue and volatile earnings pose risks. Analyst consensus is bullish with a $60.50 price target, implying 49% potential upside. Key risks include execution of restructuring and dependence on MGM performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
